Alphamab Oncology's JSKN027 IND application accepted for bispecific ADC

Alphamab Oncology announced that China's National Medical Products Administration (NMPA) has officially accepted its investigational new drug (IND) application for JSKN027. This bispecific antibody-drug conjugate (ADC) targets programmed death ligand 1 (PD-L1) and vascular endothelial growth factor receptor 2 (VEGFR2). The company plans to initiate a Phase I clinical study for JSKN027, focusing on its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in advanced malignant solid tumors, with the goal of determining the maximum tolerated dose.

JSKN027 stands out as the first PD-L1/VEGFR2 bispecific ADC globally to advance into clinical studies. Preclinical data indicates potent anti-tumor activity across both in vitro and in vivo models, alongside good tolerability demonstrated in IND-enabling tox studies. The drug employs a unique three-fold synergistic mechanism, combining targeted cell killing and bystander activity with inhibition of tumor angiogenesis and reversal of immune suppression, making it a promising treatment strategy for various solid tumors.

Alphamab Oncology, a biopharmaceutical company, specializes in ADCs, bispecific antibodies, and multi-functional protein engineering. The company's pipeline includes multiple products in late-stage clinical development, leveraging proprietary protein engineering platforms and structure-guided molecular modeling expertise.